Biotech - Today Stories

Vaxxas opens 5,500 square meter (60,000 square feet) state-of-the-art biomedical manufacturing facility in Brisbane, Queensland, which will support the production of millions of Vaxxas’ high-density microarray patches (HD-MAPs) per year for future late-stage clinical trials and first commercial vaccine products. Funded by the Queensland Government and Vaxxas, the facility showcases world-class and first-of-a-kind biomedical manufacturing capabilities. The facility contains two independent Good Manufacturing Practice (GMP), qualified aseptic cleanrooms, a medical device manufacturing space, a device assembly cleanroom, and supporting infrastructure including laboratories and office space. The facility is Vaxxas’ new global headquarters and home to 130 employees including highly-skilled an…

National Biotechnology Company Adds New Location in Louisiana BATON ROUGE, La.--(BUSINESS WIRE)--ImmunoTek Bio Centers opens its 80th and newest ImmunoTek Plasma location in Baton Rouge on Tuesday, May 2, 2023. As the world's largest independent blood and plasma donation center operator, ImmunoTek invites the Baton Rouge community to visit the state-of-the-art facility to learn more about plasma donations and how they can positively impact others. By removing the red and white blood cells from the blood, what remains is the golden liquid called plasma. Blood-plasma helps create medicines and plasma-based therapies that treat patients with various diseases and disorders, including shock and burn patients, bleeding disorders, transplant patients, those suffering from autoimmune diseases, and…

A pioneering biotech firm has secured £13.2 million to fund its mission to develop the world’s first treatment for a rare, incurable and deadly disease.   SynaptixBio, whose aim is to treat the genetic central nervous system disease TUBB4A-related leukodystrophy, has successfully raised £11.05m in its latest funding round to add to the £2.125m of seed funding from the last two years. Both rounds have come exclusively from private investment.   The Oxfordshire-based research firm believes the investment will fund the rest of its research into a treatment and take it to human clinical trials next year.   First identified in 2015, TUBB4A-related leukodystrophy, which is believed to mainly affect babies and young children, is caused by a mutation in the TUBB4A gene. It disrupts the signals bet…

Aviceda is partnering with world-renowned scientist Professor Christopher Scott and his teams at the Patrick G. Johnson Centre for Cancer Research at Queen’s University Belfast to spearhead development of the next generation of glyco-immune therapeutics. Aviceda Executives will participate in a Cancer Showcase Event as part of the 25th Anniversary of the Good Friday Agreement Conference at Queen’s to highlight Northern Ireland’s emerging global reputation in the translational oncology ecosystem. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a clinical-stage biotech company focused on developing next-generation immuno-modulators to treat diseases such as cancer, today announced a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University…

Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments CAMBRIDGE, MA and SOUTH SAN FRANCISCO, CA / ACCESSWIRE / January 5, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna's mRNA technologies and CytomX's Probody® therapeutic platform. Th…

OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines Acquisition will bolster Moderna's suite of platform technologies CAMBRIDGE, MA and TOKYO, JAPAN / ACCESSWIRE / January 4, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and OriCiro Genomics K.K., a pioneer in cell-free DNA synthesis and amplification technologies, today announced they have entered into a definitive agreement through which Moderna will acquire OriCiro for $85 million. "With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing," said Stéphane Bancel, Chief Executive Officer of Moderna. "…

LONDON, UK, 30 November 2022 – Otsuka Pharmaceuticals UK Ltd. announces that the MHRA (Medicines and Healthcare Products Regulatory Agency) has authorised Lupkynis® (voclosporin) for use in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN). The MHRA decision applies to England, Scotland, and Wales (Great Britain). Voclosporin is the first and only oral CNI licensed in Great Britain (GB) specifically for the treatment of active LN in adult patients.  “The MHRA’s authorisation of Lupkynis represents a significant development for lupus nephritis patients in Great Britain, offering voclosporin as a new combination treatment option for eligible patients.” said Ryan Gynne, Managing…

Los Angeles, California, USA, November 15, 2022 – ImaginAb Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPETTM) imaging agent and radiopharmaceutical therapy (RPT) products, today announced the signing of a new multi-year, non-exclusive license agreement with DynamiCure Biotechnology, a private biopharmaceutical company developing innovative therapeutic antibody candidates to treat cancer, autoimmune disorders, and other diseases.  Under the agreement, ImaginAb will license and supply clinical doses of its investigational CD8 ImmunoPETTM to DynamiCure Biotechnology for use in its clinical trial. Commenting on the announcement, Ian Wilson, CEO of ImaginAb, said: “We are delighted that DynamiCure Biotechnology will be using our CD8 ImmunoPET…

Singleron Biotechnologies, a leader in single cell multi-omics analysis, is happy to announce the opening of their brand-new laboratories in Cologne, Germany, dedicated to showcasing their vast single cell sequencing solutions, from instruments to novel kits tailored for many different research applications. Through customer demonstrations, these modern laboratories will provide potential customers a hands-on approach allowing the opportunity to test the latest developments Singleron has to offer in single cell sequencing. The laboratories will also augment Singleron’s productivity to extend operations in research and development of novel products to further Singleron’s innovative technology portfolio. The new state of the art laboratory will complement the already established single cell…

– Leaders in biotech and genomics to launch more personalised genomic solutions to more than 10,000 people across the Baltics and Mediterranean regions – L’AQUILA, Italy, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Biotechnology startup Longenesis has partnered with Dante Genomics, a global leader in genomics and precision medicine, to offer whole genome sequencing (WGS) to more than 10,000 existing Longenesis study participants. WGS and Dante’s subsequent genomic reports are valuable health tools that can provide physicians and individuals with information about personalised dietary choices, predisposition to genetic diseases, genetic carrier information and more. Traditionally, DNA tests have been limited in the Baltic and Mediterranean regions due to cost and availability of practitioners, servic…

CAMBRIDGE, MA / ACCESSWIRE / August 29, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it will host its in-person and virtual R&D Day at 9:00 a.m. ET on Thursday, September 8, 2022. Moderna's R&D Day will feature presentations from Stéphane Bancel, Chief Executive Officer, Stephen Hoge M.D., President, and Moderna clinical team leaders. A live webcast will be available under "Events and Presentations" in the Investors section of the Moderna website. A replay of the webcast will be archived on Moderna's website for one year following the presentation. About Moderna In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messen…

Cambridge spin-out secures Suite 7 in the Park’s Science Village Cambridge, UK, 22 August 2022: Chesterford Research Park has announced that Constructive Bio has joined the Park’s highly regarded multi-occupier R&D building, Science Village. The Cambridge-born start-up, which has recently closed a $15 million (£12.45 million) seed funding round (led by Ahren Innovation Capital with participation from Amadeus Capital, OMX Ventures and General Inception) to commercialise its technology, is taking 1,993 sq ft of space within the Park’s Science Village Building. Designed with occupier needs front-and-centre of its design, the facility provides 16 individual and self-contained R&D suites. The suites also come complete with fully fitted, ready-made labs, avoiding the need for lengthy ref…

TARRYTOWN, N.Y., July 26, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 10th annual Regeneron Prize for Creative Innovation, a competition designed to recognize excellence and creativity in biomedical research conducted by postdoctoral fellows and graduate students. Each year, Regeneron invites the country's leading research universities to nominate early career scientists. Applicants present their "dream projects" within the field of biomedical science to a committee of Regeneron scientists and leaders, describing and designing the research they would pursue if they had access to any resource or technology, to compete for the Regeneron Prize and an award of $50,000. This year's winners are Ryan Emenecker, Ph.D., of Washington Univer…

GERMANTOWN, Md., July 19, 2022 /PRNewswire/ -- Deka Biosciences announced today that it is breaking ground on a 14,000 square foot office and lab which will house a state of the art Research and Development, Process Development, and Manufacturing facility to further develop their novel cytokine therapies. This will be the first facility to house a dual targeted cytokine development lab in the DC/Maryland/Virginia region and the only company in the US developing a therapeutic of its kind. The new headquarters will be located at 20380 Seneca Meadows Parkway in Germantown, Maryland and Deka anticipates the move to be completed in the first quarter of 2023. "Our new facility will provide us with essential space to expand our research, development and manufacturing efforts, allowing us to conti…

invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), focused on research and development (R&D) and business development activities outside of China, and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives, today announced that the companies have entered into a definitive agreement whereby invoX will acquire all of the issued and outstanding shares of F-star common stock for $7.12 per share. The proposed acquisition values F-star at approximately $161 million. The transaction has been unanimously approved by the invoX and F-star Boards of Directors and is expected to close in the…

Scientific Laboratory Supplies (SLS) – the leading supplier of equipment, chemicals and consumables for laboratory use in the UK – has announced the acquisition of two businesses, Gem Scientific and Northern Balance, to expand its product and service offerings. Both companies will continue to operate as independent entities and retain all employees, whilst harnessing SLS’s business support and infrastructure to benefit all parties, stakeholders and customers.   Gem Scientific is a laboratory equipment distributor based in West Yorkshire, supplying high quality products – including hygiene testing devices and consumables – to sectors such as the food and beverage industry. This acquisition will help to strengthen both brands in this field, giving customers greater access to a wider range of…

Manufacturing facility would provide access to domestically manufactured vaccines against respiratory viruses Moderna would expand its presence in the UK through investments in R&D activities and capabilities Collaboration would support the UK with direct access to rapid pandemic response capabilities CAMBRIDGE, MA / ACCESSWIRE / June 21, 2022 / Moderna, Inc . (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement in principle with the United Kingdom government to establish an mRNA Innovation and Technology Center in the UK. This state-of-the-art mRNA vaccine manufacturing facility is expected to provide access to rapid pandemic response capabilities and Moderna's respiratory virus vaccine candidates. Additionall…

Coave Therapeutics and ABL enter into strategic collaboration to develop gene therapy manufacturing processes and create joint capabilities for process development of AAV-based gene therapy Two-stage collaboration aims to accelerate development of high-capacity manufacturing processes for AAV-based products and secure Coave’s infrastructure needs to set up its process development capabilities Paris and Strasbourg, France, June 9, 2022 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, and ABL, a pure play contract development and manufacturing organization (CDMO) specialized in the development and manufacturing of viruses for vaccine candidates, gene and cancer therap…

-New 344,000 square foot cell and genetic therapies research and manufacturing facility to be built- -Facility to support continued R&D growth- BOSTON--(BUSINESS WIRE)--May 17, 2022-- At a dedication today of the new Jeffrey Leiden Center for Cell and Genetic Therapies in Boston’s Seaport, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced plans to build another 344,000 square foot facility in the Seaport to support the company’s continued rapid growth, in particular the expansion of its cell and genetic therapies programs. With the completion of this new site expected in 2025, Vertex will occupy 1.9 million square feet of real estate in the Seaport across five sites, making it the largest biotech in Boston in terms of square footage. Jeffrey Leiden Center for Cell and Geneti…

Initial grants of approximately $5 million awarded to local and global nonprofits that support groups and causes disproportionately affected by COVID-19 CAMBRIDGE, MA / ACCESSWIRE / April 4, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the launch of the Moderna Charitable Foundation to promote public health, access to quality healthcare and educational opportunities, particularly in underserved populations. "We founded Moderna based upon the idea that we can make a transformative positive impact through our medicines, and the work of the Moderna Charitable Foundation will accelerate our efforts to improve health globally, particularly for those with inadequate access to health and medicine," said Noub…